<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648830</url>
  </required_header>
  <id_info>
    <org_study_id>CAI-P4-057</org_study_id>
    <nct_id>NCT00648830</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Clarithromycin 250 mg Tablets</brief_title>
  <official_title>Randomized Single Dose Crossover Replicate Comparative Bioavailability Study of Clarithromycin 250 mg Tablets in Healthy Male and Female Volunteers Under Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genpharm ULC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Genpharm's&#xD;
      clarithromycin tablets following a single, oral 250 mg (1 x 250 mg) dose compared to the&#xD;
      Biaxin® filmtab® (Abbott Laboratories USA) administered under fasted conditions. Thirty-four&#xD;
      (34) healthy, light-, non- or ex-smoking subjects of at least 18 a years of age were&#xD;
      randomized, in this four-period, two-treatment crossover bioequivalence study conducted by&#xD;
      Eric Sicard, M.D. at Algorithme Pharma Inc. Montreal, Canada.&#xD;
&#xD;
      Statistical analysis of the data reveals that 90% confidence intervals are within the&#xD;
      acceptable bioequivalent range of 80% and 125% for the natural log transformed parameters&#xD;
      AUCT, AUCI and Cmax. This study demonstrates that Genpharm's clarithromycin 250 mg tablets&#xD;
      are bioequivalent to Biaxin® filmtab® 250 mg tablets (Abbott Laboratories USA) administered&#xD;
      under fasted conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (AUC &amp; Cmax)</measure>
    <time_frame>within 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clarithromycin 250 mg immediate-release oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biaxin® (Clarithromycin) 250 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Single-dose of Clarithromycin 250 mg oral immediate-release tablets</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Biaxin®, Biaxin® Filmtabs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>single-dose 250 mg immediate-release oral tablets</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects meeting all of the following criteria may be included in the study:&#xD;
&#xD;
        Availability of volunteer for the entire study period and willingness to adhere to protocol&#xD;
        requirements as evidenced by the informed consent form (ICF) duly signed by the volunteer&#xD;
&#xD;
        Males or females aged of at least 18 years with a body mass index (BMI) greater or equal to&#xD;
        19 and below 30 kg/m2&#xD;
&#xD;
        Clinical laboratory values within the laboratory's stated normal range; if not within this&#xD;
        range, they must be without any clinical significance (laboratory tests are presented in&#xD;
        section 6.1.1.3)&#xD;
&#xD;
        Healthy according to the laboratory results and physical examination&#xD;
&#xD;
        Light , non or ex smokers. Light smokers are defined as someone smoking 10 cigarettes or&#xD;
        less per day, and ex smokers are defined as someone who completely stopped smoking for at&#xD;
        least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Significant history of hypersensitivity to clarithromycin, erythromycin, other macrolide&#xD;
        antibacterial agents or any related products as well as severe hypersensitivity reactions&#xD;
        (like angioedema) to any drugs&#xD;
&#xD;
        Presence or history of significant gastrointestinal, liver or kidney disease, or any other&#xD;
        conditions known to interfere with the absorption, distribution, metabolism or excretion of&#xD;
        drugs or known to potentiate or predispose to undesired effects&#xD;
&#xD;
        Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic,&#xD;
        psychiatric, endocrine, immunologic or dermatologic disease&#xD;
&#xD;
        Presence of significant heart disease or disorder according to ECG&#xD;
&#xD;
        Females who are pregnant, lactating or are likely to become pregnant during the study&#xD;
&#xD;
        Females of childbearing potential or females taking systemic contraceptives who refuse to&#xD;
        use one of the acceptable contraceptive regimen (described in section 5.4.9) throughout the&#xD;
        study&#xD;
&#xD;
        Positive HCG beta serum pregnancy test before or during the study&#xD;
&#xD;
        Maintenance therapy with any drug, or significant history of drug dependency or alcohol&#xD;
        abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)&#xD;
&#xD;
        Any clinically significant illness in the previous 28 days before day 1 of this study&#xD;
&#xD;
        Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all&#xD;
        barbiturates, corticosteroids, phenylhydantoins, etc.)&#xD;
&#xD;
        Participation in another clinical trial in the previous 28 days before day 1 of this study&#xD;
&#xD;
        Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical&#xD;
        studies, etc.) in the previous 56 days before day 1 of this study&#xD;
&#xD;
        Positive urine screening of drugs of abuse (drugs listing is presented in section 6.1.1.4)&#xD;
&#xD;
        Positive results to HIV, HBsAg or anti-HCV tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H7V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Elliot Offman, Director, Biopharmaceutics</name_title>
    <organization>Genpharm ULC</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

